[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Miyazaki et al., 2014 - Google Patents

Expression of prorenin receptor in renal biopsies from patients with IgA nephropathy

Miyazaki et al., 2014

View HTML
Document ID
4389826573309571230
Author
Miyazaki N
Murata I
Takemura G
Okada H
Kanamori H
Matsumoto-Miyazaki J
Yoshida G
Izumi K
Kashi H
Niimi K
Nishiwaki A
Miyazaki T
Ohno M
Ohashi H
Suzuki F
Minatoguchi S
Publication year
Publication venue
International Journal of Clinical and Experimental Pathology

External Links

Snippet

Prorenin receptor (PRR) has been implicated in the onset and progression of various renal diseases, though its possible association with immunoglobulin A (IgA) nephropathy remains unclear. In the present study, we tried to clarify expression and pathophysiological …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Similar Documents

Publication Publication Date Title
Sethi et al. Protocadherin 7–associated membranous nephropathy
Al-Rabadi et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy
Sethi et al. Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1
CN110187120B (en) Methods and compositions for the detection and treatment of preeclampsia
Cosio et al. Transplant glomerulopathy
Winn et al. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2
Said et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis
JP6055464B2 (en) Reduction of circulating soluble urokinase receptor
Gibier et al. Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis
WO2021058548A1 (en) Antibodies for the diagnosis and/or treatment of atherosclerosis
Klomjit et al. Fibrillary glomerulonephritis and DnaJ homolog subfamily B member 9 (DNAJB9)
Paueksakon et al. Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining
JP2015529633A (en) BAG3 as a biochemical serum marker and tissue marker
Dakhlallah et al. Constitutive AKT activity predisposes lung fibrosis by regulating macrophage, myofibroblast and fibrocyte recruitment and changes in autophagy
Miyazaki et al. Expression of prorenin receptor in renal biopsies from patients with IgA nephropathy
Wang et al. Upregulation of C/EBP homologous protein induced by ER stress mediates epithelial to Myofibroblast transformation in ADTKD-UMOD
Cárdenas et al. Up-regulation of the kinin B2 receptor pathway modulates the TGF-β/Smad signaling cascade to reduce renal fibrosis induced by albumin
Tsuruta et al. Antiphospholipid antibodies and renal outcomes in patients with lupus nephritis
WO2021058553A1 (en) Methods for the diagnosis of atherosclerosis
Balcomb et al. SMOC1 colocalizes with Alzheimer’s disease neuropathology and delays Aβ aggregation
Izumi et al. Tenascin-C expression in renal biopsies from patients with tubulointerstitial nephritis and its relation to disease activity and prognosis
Siegerist et al. The Regulation of MAGI2 and its Diagnostic Application in Podocytopathies
Gerlach et al. The tricellular junctional protein Ildr2 helps maintain glomerular podocyte architecture
Gong et al. Dynamic regulation of proximal tubular autophagy from injury to repair after ischemic kidney damage
Srivastava et al. 10 Asymptomatic Hematuria and Proteinuria